Home LiteratureArticle Details
PMID: 6821202 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Antibody response to Pseudomonas aeruginosa exoproducts in cancer patients.

Journal of clinical microbiology ·Vol. 15 ·No. 1 ·1982-01-00 ·Pages 115-22

Crowe KE, Bass JA, Young VM, Straus DC

Abstract

We analyzed sera from 28 patients with various types of malignancies for the occurrence of antibodies against exotoxin A of Pseudomonas aeruginosa and two Pseudomonas proteases. A total of 27 of these individuals were colonized or infected with P. aeruginosa at one time or another during the study, whereas the remaining patient was colonized with four non-P. aeruginosa species of Pseudomonas. Sera were obtained from several of these patients before P. aeruginosa colonization or infection of these individuals was detected, which provided an opportunity to evaluate their responsiveness to pseudomonal exoproducts as they acquired the organism. Exotoxin A was purified from culture supernatant fluids of strain PA-103, and the two proteases were purified from an isolate of strain JR3, a highly proteolytic strain originally recovered from the sputum of a cystic fibrosis patient. Antibodies to the exotoxin A and the two proteases were detected in these sera, and sera which contained relatively high antibody levels to exotoxin A afforded mice complete protection against lethal challenges with this substance. Statistical analyses showed that patients infected with P. aeruginosa had consistently higher antibody levels (P less than 0.005) to the exoproducts than patients who were colonized with this organism. Also, patients colonized with P. aeruginosa possessed significantly higher antibody levels (P less than 0.003) to these three exoproducts than uninfected, hospitalized patients. Parke-Davis type 1 was the strain most commonly isolated from these patients (46%), but colonization or infection due to this organism usually resulted in the production of low levels of antibody to Pseudomonas exoproducts. However, infections with Parke-David type 7 organisms were always associated with intermediate- and high-responder sera to exotoxin A. These results indicated that potentially toxic products were elaborated during the course of cancer-related colonization and infection with P. aeruginosa.

MeSH Terms
ADP Ribose Transferases Animals Antibody Formation Bacterial Toxins Exotoxins/immunology Humans Mice Neoplasms/immunology,microbiology Pseudomonas aeruginosa/immunology Radioimmunoassay Virulence Factors
Chemicals
Bacterial Toxins Exotoxins Virulence Factors ADP Ribose Transferases toxA protein, Pseudomonas aeruginosa
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Crowe K E
Bass J A
Young V M
Straus D C
References (21)
21 references, click to expand
  1. Characteristics of nonbacteremic Pseudomonas pneumonia.
    Ann Intern Med. 1968 Feb;68(2):295-307 PMID: 4306124
  2. INTRACELLULAR HEMOLYSIN OF PSEUDOMONAS AERUGINOSA.
    J Bacteriol. 1963 Mar;85:522-6 PMID: 14042927
  3. Serogroups of Pseudomonas aeruginosa and the immune response of patients with cystic fibrosis.
    J Infect Dis. 1970 Mar;121(3):269-74 PMID: 4984335
  4. Epidemiological studies of Pseudomonas species in patients with leukemia.
    Am J Med Sci. 1970 Aug;260(2):82-9 PMID: 5506899
  5. Pseudomonas bacteremia in patients with malignant diseases.
    Am J Med Sci. 1970 Oct;60(4):216-23 PMID: 4322162
  6. Pseudomonas pneumonia: a prototype of hospital-based infection.
    Radiology. 1972 Dec;105(3):555-62 PMID: 4628923
  7. NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,.
    Proc Natl Acad Sci U S A. 1975 Jun;72(6):2284-8 PMID: 166383
  8. Serotyping of Pseudomonas aeruginosa isolates from patients with cystic fibrosis of the pancreas.
    J Clin Microbiol. 1975 Jun;1(6):521-6 PMID: 809484
  9. Large-scale purification and characterization of the exotoxin of Pseudomonas aeruginosa.
    Infect Immun. 1976 Oct;14(4):1077-86 PMID: 11187
  10. Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: evidence for in vivo toxin production during infection.
    Infect Immun. 1976 Oct;14(4):942-7 PMID: 825470
  11. Serum antibody to Pseudomonas aeruginosa exotoxin measured by a passive hemagglutination assay.
    J Clin Microbiol. 1977 Jul;6(1):58-61 PMID: 407250
  12. Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections.
    Infect Immun. 1977 Dec;18(3):596-602 PMID: 412786
  13. Mechanism of action of Pseudomonas aeruginosa exotoxin A in experimental mouse infections: adenosine diphosphate ribosylation of elongation factor 2.
    Infect Immun. 1978 Jan;19(1):29-33 PMID: 415004
  14. Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay.
    J Infect Dis. 1978 Jul;138(1):49-8 PMID: 98596
  15. Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.
    J Clin Invest. 1979 Feb;63(2):276-86 PMID: 429553
  16. Assessment of protease (elastase) as a Pseudomonas aeruginosa virulence factor in experimental mouse burn infection.
    Infect Immun. 1979 Apr;24(1):181-7 PMID: 110690
  17. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: extracellular protease and elastase as in vivo virulence factors.
    Can J Microbiol. 1979 May;25(5):593-9 PMID: 89891
  18. Immunologic investigations of mucoid strains of Pseudomonas aeruginosa: comparison of susceptibility to opsonic antibody in mucoid and nonmucoid strains.
    J Infect Dis. 1980 Feb;141(2):238-47 PMID: 6444976
  19. Role of adherence in the pathogenesis of Pseudomonas aeruginosa lung infection in cystic fibrosis patients.
    Infect Immun. 1980 Dec;30(3):694-9 PMID: 7014444
  20. PSEUDOMONAS AERUGINOSA ELASTASE. ISOLATION, CRYSTALLIZATION, AND PRELIMINARY CHARACTERIZATION.
    J Biol Chem. 1965 Aug;240:3295-304 PMID: 14321366
  21. New immunotype schema for Pseudomonas aeruginosa based on protective antigens.
    J Bacteriol. 1969 May;98(2):835-6 PMID: 4977486
Article Info
Journal
Journal of clinical microbiology
Abbr.
J Clin Microbiol
ISSN
0095-1137
Published
1982-01-00
Pages
115-22
Language
English
Region
United States
NLM ID
7505564
PMCID
PMC272035
Subset
IM
Grants
NHLBI NIH HHS · HL 23578 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com